CatalYm is a German biopharmaceutical company pioneering immunotherapies that target Growth Differentiation Factor-15 (GDF-15), a protein exploited by tumors to suppress immune responses. Their lead candidate, visugromab, is a monoclonal antibody designed to neutralize GDF-15, thereby restoring the immune system's ability to attack solid tumors.

Founded in 2016 as a spin-off from the Julius-Maximilians-University of Würzburg, CatalYm is headquartered in Planegg-Martinsried, Germany. The company has demonstrated that visugromab, especially when combined with anti-PD-1 therapies, can induce durable tumor responses in patients who have relapsed or are refractory to standard treatments. Additionally, visugromab shows potential in alleviating cancer-associated cachexia, a condition characterized by severe weight and muscle loss.